| ISSN |
2218-4333 (online) |
| Open Access |
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/ |
| Copyright |
© The Author(s) 2019. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Oncology |
| Manuscript Type |
Review |
| Article Title |
Management of oligometastatic non-small cell lung cancer patients: Current controversies and future directions
|
| Manuscript Source |
Invited Manuscript |
| All Author List |
Felipe Couñago, Javier Luna, Luis Leonardo Guerrero, Blanca Vaquero, María Cecilia Guillén-Sacoto, Teresa González-Merino, Begoña Taboada, Verónica Díaz, Belén Rubio-Viqueira, Ana Aurora Díaz-Gavela, Francisco José Marcos and Elia del Cerro |
| ORCID |
|
| Funding Agency and Grant Number |
|
| Corresponding Author |
Felipe Couñago, MD, PhD, Doctor, Professor, Staff Physician, Department of Radiation Oncology, Hospital Universitario Quirónsalud Madrid, Calle Diego de Velázquez 1, Pozuelo de Alarcón, Madrid 28223, Spain. fcounago@gmail.com |
| Key Words |
Non-small cell lung cancer; Metastasectomy; Oligometastases; Stereotactic ablative radiotherapy; Stereotactic body radiation therapy; Radiosurgery |
| Core Tip |
In recent years, numerous studies, including two randomized phase II trials, have demonstrated that local treatment-either radiotherapy or surgery-of the primary tumour and metastases improves progression-free survival and overall survival in patients who present with oligometastatic non-small cell lung cancer at diagnosis and in those who respond to the initial systemic therapy. As we await the results of ongoing randomized phase III trials, the main international clinical guidelines recommend a multimodal strategy to manage this subgroup of oligometastatic patients. Current guidelines recommend systemic therapy combined with local treatment of the metastases and, if applicable, the primary tumour. |
| Publish Date |
2019-10-25 08:06 |
| Citation |
Couñago F, Luna J, Guerrero LL, Vaquero B, Guillen-Sacoto MC, González-Merino T, Taboada B, Díaz V, Rubio-Viqueira B, Díaz-Gavela AA, Marcos FJ, del Cerro E. Management of oligometastatic non-small cell lung cancer patients: Current controversies and future directions. World J Clin Oncol 2019; 10(9): 318-339 |
| URL |
https://www.wjgnet.com/2218-4333/full/v10/i10/318.htm |
| DOI |
https://dx.doi.org/10.5306/wjco.v10.i10.318 |
